Search research articles
Contact Us
Filters
Showing results (31-40 of 38) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 38 results.
JAMA Oncology
|
September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial
Leora Horn, Ziping Wang, Gang Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.
The Lancet. Respiratory Medicine
|
October 20, 2019
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yunpeng Yang, Jianya Zhou, Jianying Zhou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2021
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration
Andrew D J Pearson, Elly Barry, Yael P Mossé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 15, 2021
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing
Yunpeng Yang, Jie Huang, Tao Wang, et al.
Cancer Communications (London, England)
|
February 29, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
Jing Zheng, Tao Wang, Yunpeng Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2005
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study
Paolo Maione, Francesco Perrone, Ciro Gallo, et al.
British Journal of Cancer
|
September 11, 2003
Supportive care in patients with advanced non-small-cell lung cancer
M Di Maio, F Perrone, C Gallo, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 38) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 38 results.
JAMA Oncology
|
September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial
Leora Horn, Ziping Wang, Gang Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.
The Lancet. Respiratory Medicine
|
October 20, 2019
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yunpeng Yang, Jianya Zhou, Jianying Zhou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2021
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration
Andrew D J Pearson, Elly Barry, Yael P Mossé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 15, 2021
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing
Yunpeng Yang, Jie Huang, Tao Wang, et al.
Cancer Communications (London, England)
|
February 29, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
Jing Zheng, Tao Wang, Yunpeng Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2005
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study
Paolo Maione, Francesco Perrone, Ciro Gallo, et al.
British Journal of Cancer
|
September 11, 2003
Supportive care in patients with advanced non-small-cell lung cancer
M Di Maio, F Perrone, C Gallo, et al.
Page
of 4